A double-blind, placebo-controlled, pharmacokinetics, safety, and tolerability study to evaluate the single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy japanese subjects

Trial Profile

A double-blind, placebo-controlled, pharmacokinetics, safety, and tolerability study to evaluate the single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy japanese subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2015

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 21 Oct 2015 New trial record
    • 12 Oct 2015 Results published in Clinical Drug Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top